See more : C-Bond Systems, Inc. (CBNT) Income Statement Analysis – Financial Results
Complete financial analysis of Invitae Corporation (NVTA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Invitae Corporation, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- Akzo Nobel India Limited (AKZOINDIA.NS) Income Statement Analysis – Financial Results
- Doriemus Plc (DOR.AX) Income Statement Analysis – Financial Results
- Delta Plus Group (0RUJ.L) Income Statement Analysis – Financial Results
- Teck Resources Limited (TECK) Income Statement Analysis – Financial Results
- Pearl Green Clubs and Resorts (PGCRL.BO) Income Statement Analysis – Financial Results
Invitae Corporation (NVTA)
About Invitae Corporation
Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 516.30M | 460.45M | 279.60M | 216.82M | 147.70M | 68.22M | 25.05M | 8.38M | 1.60M | 148.00K | 0.00 |
| Cost of Revenue | 417.26M | 348.67M | 198.28M | 118.10M | 80.11M | 50.14M | 27.88M | 16.52M | 5.62M | 667.00K | 0.00 |
| Gross Profit | 99.05M | 111.78M | 81.32M | 98.72M | 67.59M | 18.08M | -2.83M | -8.15M | -4.02M | -519.00K | 0.00 |
| Gross Profit Ratio | 19.18% | 24.28% | 29.09% | 45.53% | 45.76% | 26.50% | -11.30% | -97.22% | -250.62% | -350.68% | 0.00% |
| Research & Development | 402.09M | 416.09M | 240.61M | 141.53M | 63.50M | 46.47M | 44.63M | 42.81M | 22.14M | 16.04M | 5.56M |
| General & Administrative | 192.31M | 248.07M | 324.57M | 79.07M | 52.23M | 39.47M | 24.09M | 16.05M | 12.61M | 5.76M | 3.00M |
| Selling & Marketing | 218.88M | 225.91M | 168.32M | 122.24M | 74.43M | 53.42M | 28.64M | 22.48M | 8.76M | 2.43M | 0.00 |
| SG&A | 411.20M | 473.98M | 492.89M | 201.31M | 126.66M | 92.89M | 52.72M | 38.53M | 21.37M | 8.20M | 3.00M |
| Other Expenses | 8.05M | 25.68M | -32.33M | -3.89M | -2.57M | -303.00K | 348.00K | -94.00K | -79.00K | -26.00K | 2.00K |
| Operating Expenses | 813.28M | 890.07M | 733.50M | 342.83M | 190.15M | 139.36M | 97.35M | 81.33M | 43.51M | 24.23M | 8.56M |
| Cost & Expenses | 1.23B | 1.24B | 931.77M | 460.94M | 270.26M | 189.50M | 125.23M | 97.86M | 49.13M | 24.90M | 8.56M |
| Interest Income | 56.75M | 49.90M | 29.77M | 12.41M | 0.00 | 0.00 | 0.00 | 211.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 56.75M | 49.90M | 29.77M | 12.41M | 7.03M | 3.65M | 421.00K | 0.00 | 61.00K | 59.00K | 43.00K |
| Depreciation & Amortization | 150.13M | 106.15M | 6.72M | 12.32M | 13.54M | 9.18M | 6.55M | 5.32M | 2.32M | 928.00K | 277.00K |
| EBITDA | -3.12B | -391.64M | -652.17M | -244.11M | -111.59M | -121.58M | -93.63M | -89.48M | -45.19M | -23.85M | -8.28M |
| EBITDA Ratio | -109.26% | -145.97% | -230.85% | -106.91% | -75.55% | -178.22% | -398.57% | -1,068.00% | -2,968.02% | -16,115.54% | 0.00% |
| Operating Income | -714.24M | -778.29M | -652.17M | -244.11M | -122.56M | -121.28M | -100.18M | -89.48M | -47.53M | -24.75M | -8.56M |
| Operating Income Ratio | -138.34% | -169.03% | -233.25% | -112.59% | -82.98% | -177.77% | -399.96% | -1,068.00% | -2,963.09% | -16,725.00% | 0.00% |
| Total Other Income/Expenses | -2.44B | 362.42M | -62.10M | -16.30M | -9.60M | -3.96M | -73.00K | -305.00K | 36.00K | -85.00K | -41.00K |
| Income Before Tax | -3.15B | -415.86M | -714.27M | -260.42M | -132.16M | -125.24M | -100.26M | -89.78M | -47.67M | -24.84M | -8.60M |
| Income Before Tax Ratio | -610.34% | -90.32% | -255.46% | -120.10% | -89.48% | -183.57% | -400.26% | -1,071.64% | -2,971.82% | -16,782.43% | 0.00% |
| Income Tax Expense | -44.90M | -36.86M | -105.40M | -18.45M | -2.80M | -1.86M | -5.78M | -5.11M | -2.33M | 33.00K | 45.00K |
| Net Income | -3.11B | -379.01M | -608.87M | -241.97M | -129.36M | -123.38M | -100.26M | -89.78M | -47.67M | -24.84M | -8.60M |
| Net Income Ratio | -601.64% | -82.31% | -217.77% | -111.60% | -87.58% | -180.85% | -400.26% | -1,071.64% | -2,971.82% | -16,782.43% | 0.00% |
| EPS | -13.18 | -1.80 | -4.52 | -2.66 | -1.94 | -2.65 | -3.02 | -3.18 | -1.60 | -1.67 | -0.58 |
| EPS Diluted | -13.18 | -1.80 | -4.52 | -2.66 | -1.94 | -2.65 | -3.02 | -3.18 | -1.60 | -1.67 | -0.58 |
| Weighted Avg Shares Out | 235.68M | 210.95M | 134.59M | 90.86M | 66.75M | 46.51M | 33.18M | 28.21M | 29.80M | 14.88M | 14.88M |
| Weighted Avg Shares Out (Dil) | 235.68M | 210.95M | 134.59M | 90.86M | 66.75M | 46.51M | 33.18M | 28.21M | 29.80M | 14.88M | 14.88M |
Invitae Corporation (NVTA) Q3 2023 Earnings Call Transcript
Invitae Corporation (NYSE:NVTA ) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Hoki Luk - VP, IR and Corporate Development Ken Knight - President & CEO Ana Schrank - CFO Conference Call Participants Isabella Prugue...
Invitae (NVTA) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for Invitae (NVTA) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Invitae Launches Enhanced Chemistry of MRD Test to Better Serve Biopharmaceutical Clinical and Research Partnerships
– Helps to detect circulating tumor DNA (ctDNA) as a biomarker in clinical research and clinical trials for solid tumor malignancies – – May provide real-time data on therapy response, support patient prognostic stratification and enable early detection of residual...
3 Things About Invitae Every Smart Investor Knows
Invitae's stock is down and it might get delisted from its stock exchange. It has a new crop of top managers, but it's running low on cash.
Invitae to Announce Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
SAN FRANCISCO , Nov. 1, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that it will report its third quarter 2023 financial results on Wednesday, November 8, 2023, and will host a conference call and webcast...
Is Invitae Stock a Buy Now?
Invitae's revenue has climbed over time thanks to a vast portfolio of genetic tests. At the same time, the company has struggled to turn that into profitability.
3 Penny Stocks That Look Like Intriguing Bets for the Long-Term
While penny stocks offer high potential gains, they are among the riskiest sub-$5 investments an investor can make. The low stock price penny stocks offer often reflects weak business models, high debt, and uncertain prospects.
Landmark Study Reveals Magnitude of Uncertain Results in Clinical Genetic Testing for Hereditary Disease, Points to Evidence-Based Solutions to Reach Definitive Results
– Findings set to enhance patient care and reduce uncertainty in test results as clinicians advance precision healthcare for hereditary disease – SAN FRANCISCO , Oct. 25, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced...
Invitae Appoints Dr. David Sholehvar as Chief Operating Officer
SAN FRANCISCO , Oct. 19, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced the appointment of veteran healthcare leader David Sholehvar, M.D., as chief operating officer, effective November 13, 2023.
Rural Hospital System Demonstrates the Clinical Benefits of Implementing Universal Hereditary Cancer Testing in Patients with Breast Cancer
– Invitae retrospective analysis reinforces the clinical actionability of following the ASBrS guidelines – – Testing results informed clinical management and suggest that genetics-informed care may improve patient outcomes and optimize resource utilization – SAN FRANCISCO , Oct. 12 ,...
Source: https://incomestatements.info
Category: Stock Reports